EB Pharma Developments

EB Pharma Developments has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5,298 and a net result of -€1,347. Equity is shrinking by ~27% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2027. Its solvency ranks better than 40% of 779 sector peers (NACE 74, fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).